Kairos Pharma reports news as a clinical-stage biopharmaceutical company developing cancer therapeutics designed to address drug resistance and immune suppression. Its updates center on ENV-105, also described as carotuximab, a CD105-targeting antibody program studied in prostate cancer and non-small cell lung cancer, along with broader oncology pipeline and structural-biology themes.
Company news also covers scientific conference presentations, clinical-data disclosures, annual meeting and shareholder matters, award recognition, and annual filing updates. Kairos has stated that ENV-105 has not been approved as safe or effective by the FDA or comparable foreign regulators.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO and Chairman Dr. John Yu will deliver a corporate overview presentation, which will be available on-demand starting at 7:00 AM Eastern Time on September 5, 2025. The conference will take place at the Lotte New York Palace Hotel from September 8-10, 2025.
Investors can access the presentation webcast through the company's investor relations website, with a replay available for 90 days. One-on-one meetings with Dr. Yu can be scheduled through the conference registration system.
Kairos Pharma (NYSE American:KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.
The company's CEO and Chairman, Dr. John Yu, will be available for one-on-one meetings throughout the conference. The presentation will be accessible virtually through the company's website at kairospharma.com.
Kairos Pharma (NYSE American:KAPA) has reported positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer (mCRPC) patients. The interim analysis from the first ten patients showed the drug was well-tolerated when combined with apalutamide, with no dose-limiting toxicities or unexpected adverse events.
The randomized Phase 2 trial aims to enroll 100 patients across three medical centers, evaluating ENV-105's safety and early efficacy in men whose disease has progressed despite hormone-based therapies. Interim efficacy data is expected in September 2025, and the company plans to discuss potential Phase 3 study design with regulators.
Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's CEO and Chairman, John Yu, MD, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Interested participants can register for meetings by contacting John Perez at jperez@dboralcapital.com.
Kairos Pharma (NYSE American: KAPA) has announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, scheduled for May 30-June 3, 2025, in Chicago. The company will present a poster on June 2 titled 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity.' CEO John Yu expressed enthusiasm about sharing data on their platform assets at this prestigious oncology meeting, highlighting KROS 101's potential in optimizing cancer treatment.
Kairos Pharma (NYSE: KAPA) provided a stockholder update highlighting its clinical progress and future outlook. The company is conducting two clinical trials for its lead drug ENV105: a Phase 2 trial for prostate cancer and a Phase 1 trial for EGFR-dependent non-small cell lung cancer. The company received an $876,000 Department of Defense grant for biomarker studies.
Trial sites have expanded beyond Cedars Sinai Hospital to include the University of Utah and City of Hope, with safety and interim efficacy results expected by Q2 2025. The company is also developing KROS101, a GITR ligand small molecule agonist for cancer treatment, with data presented at multiple scientific conferences.
The company maintains a strong financial position through recent private placement and non-dilutive funding, with research coverage from multiple investment banks including EF Hutton and HC Wainwright.
Kairos Pharma (NYSE American: KAPA) has received a $876,000 Department of Defense grant to support research identifying biomarkers in non-small cell lung cancer patients who develop resistance to osimertinib treatment. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick's laboratory.
The company is currently conducting a Phase 1 trial of its lead compound ENV105 in combination with osimertinib for EGFR-driven lung cancer patients who fail to respond to single-agent osimertinib. The funded research aims to develop strategies for early detection of drug resistance and identify patients who would benefit most from ENV105 treatment, potentially improving overall survival and quality of life for patients.
Kairos Pharma (NYSE: KAPA) has completed the safety lead-in phase of its Phase 2 clinical trial for ENV105 in treating metastatic, castration-resistant prostate cancer. The trial combines ENV105 with apalutamide, a standard prostate cancer treatment.
The study consists of two parts: the completed safety lead-in and an ongoing randomized portion comparing apalutamide alone versus apalutamide with ENV105. The company expects to release safety and efficacy data from the safety arm in the first half of 2025.
Patient enrollment continues for the randomization arm at cancer centers in Los Angeles and Salt Lake City. The trial includes biomarker validation to identify patients most likely to benefit from the combination therapy. The study is supported by Kairos Pharma and a National Cancer Institute grant.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in several key scientific and industry events. The company presented their novel GITR Agonist KROS 101 research at the Society for Immunotherapy of Cancer Spring Scientific Meeting on March 12, 2025, and attended the BIO Europe conference in Milan.
Upcoming events include participation in the Fierce Pharma Engage Business Development meeting in San Diego (April 29-May 1) and a presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 20-June 5). The company recently received research coverage initiation from Maxim Group on March 27.
CEO John Yu highlighted that Phase 2 trials for ENV105 are advancing, while their KROS platform shows promise in cancer immunotherapy, demonstrating the company's commitment to oncology program development and shareholder value creation.